The BioPharm Brief: Cell Therapy, Capacity, and Contracts

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Here’s what we’re talking about today.

First, Resolution Therapeutics has completed enrollment in its phase 1/2 EMERALD trial of RTX001 for end-stage liver disease. The trial is evaluating the company’s investigational engineered macrophage therapy, which is designed to promote tissue repair and regeneration in patients with advanced liver disease. Resolution says all 15 planned patients have now been dosed, with interim clinical data expected in the fourth quarter of 2026. The company is also planning a phase 3 program as it continues to evaluate RTX001’s potential in liver disease.

In manufacturing news, Samsung Biologics has signed a $262 million biologics manufacturing agreement with an undisclosed European pharmaceutical company. The agreement extends through 2033 and will involve manufacturing at Samsung Biologics’ facilities in Songdo, South Korea. The deal adds to the company’s growing contract manufacturing business as biopharma companies continue to rely on external manufacturing partners for biologic drug production.

And CordenPharma is investing $80 million to expand its sterile injectable manufacturing capacity. The investment will increase the company’s annual capacity to 500 million units and support additional sterile injectable production. The expansion comes as manufacturers continue to invest in capacity for complex and high-demand injectable products.

That’s The BioPharm Brief for today. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways:

• Resolution: RTX001 enrollment is complete, with interim data expected in Q4.
• Samsung: A new $262 million deal expands its long-term biologics manufacturing commitments.
• CordenPharma: An $80 million investment will raise sterile injectable capacity to 500 million units annually.